Mon, September 19, 2022
Fri, September 16, 2022
Thu, September 15, 2022
Wed, September 14, 2022
Tue, September 13, 2022
Mon, September 12, 2022
Fri, September 9, 2022
Thu, September 8, 2022
Wed, September 7, 2022

Paul Matteis Maintained (BIIB) at Hold with Decreased Target to $223 on, Sep 12th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-decreased-target-to-223-on-sep-12th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Paul Matteis of Stifel, Maintained "Biogen Inc." (BIIB) at Hold with Decreased Target from $230 to $223 on, Sep 12th, 2022.

Paul has made no other calls on BIIB in the last 4 months.



There are 5 other peers that have a rating on BIIB. Out of the 5 peers that are also analyzing BIIB, 1 agrees with Paul's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Carter Gould of "Barclays" Maintained at Hold with Decreased Target to $200 on, Thursday, July 21st, 2022


These are the ratings of the 4 analyists that currently disagree with Paul


  • Ami Fadia of "Needham" Maintained at Strong Buy with Decreased Target to $250 on, Thursday, July 21st, 2022
  • Phil Nadeau of "Cowen & Co." Maintained at Buy with Decreased Target to $270 on, Thursday, July 21st, 2022
  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Decreased Target to $270 on, Thursday, July 21st, 2022
  • Jay Olson of "Oppenheimer" Maintained at Buy with Increased Target to $230 on, Monday, July 18th, 2022

Publication Contributing Sources